United States · Health Care · USD · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
Sector average (own scale)
Amounts in USD; stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Indaptus Therapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -587.59% | 286.67% | 74.14% | 42.57% | 29.86% | 22.99% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -250.45% | -339.35% | -700.23% | -700.23% | -700.23% | -700.23% |
| Total Assets | $9,310,168.00 | $2,977,436.81 | $2,977,436.81 | $2,977,436.81 | $2,977,436.81 | $2,977,436.81 |
| Sector average | $3,280,499,225.95 | $3,298,345,309.75 | $3,676,894,011.56 | |||
| Net Income | -$20,848,916.00 | -$20,848,916.00 | -$20,848,916.00 | -$20,848,916.00 | -$20,848,916.00 | -$20,848,916.00 |
| $4,262,561,283.40 |
| $4,994,412,918.01 |
| $5,761,557,240.51 |